Hemangiomas are rare, benign vascular neoplasms that are more common in patients with end-stage renal disease. Here, we describe 2 cases of hemangioma misdiagnosed as renal cell carcinoma before renal transplantation. The key finding in our case was the misdiagnosis of hemangiomas as renal cell carcinoma based on computed tomography and magnetic resonance imaging in patients with end-stage renal disease. Because living transplantation was planned for our patients, we performed rapid surgical resection of the heterogeneously enhancing renal masses to avoid delays in transplantation. Our case highlights the importance of rapid surgical resection of enhanced renal masses to confirm diagnosis, thereby avoiding delays in patients scheduled for renal transplantation.

Hemangiomas are rare, benign vascular neoplasms that are more common in patients with end-stage renal disease. Here, we describe 2 cases of hemangioma misdiagnosed as renal cell carcinoma before renal transplantation. The key finding in our case was the misdiagnosis of hemangiomas as renal cell carcinoma based on computed tomography and magnetic resonance imaging in patients with end-stage renal disease. Because living transplantation was planned for our patients, we performed rapid surgical resection of the heterogeneously enhancing renal masses to avoid delays in transplantation. Our case highlights the importance of rapid surgical resection of enhanced renal masses to confirm diagnosis, thereby avoiding delays in patients scheduled for renal transplantation.

Hemangiomas are rare, benign vascular neoplasms that are more common in patients with end-stage renal disease. Here, we describe 2 cases of hemangioma misdiagnosed as renal cell carcinoma before renal transplantation. The key finding in our case was the misdiagnosis of hemangiomas as renal cell carcinoma based on computed tomography and magnetic resonance imaging in patients with end-stage renal disease. Because living transplantation was planned for our patients, we performed rapid surgical resection of the heterogeneously enhancing renal masses to avoid delays in transplantation. Our case highlights the importance of rapid surgical resection of enhanced renal masses to confirm diagnosis, thereby avoiding delays in patients scheduled for renal transplantation.

Hemangiomas are rare, benign vascular neoplasms that are more common in patients with end-stage renal disease. Here, we describe 2 cases of hemangioma misdiagnosed as renal cell carcinoma before renal transplantation. The key finding in our case was the misdiagnosis of hemangiomas as renal cell carcinoma based on computed tomography and magnetic resonance imaging in patients with end-stage renal disease. Because living transplantation was planned for our patients, we performed rapid surgical resection of the heterogeneously enhancing renal masses to avoid delays in transplantation. Our case highlights the importance of rapid surgical resection of enhanced renal masses to confirm diagnosis, thereby avoiding delays in patients scheduled for renal transplantation.

Hemangiomas are rare, benign vascular neoplasms that are more common in patients with end-stage renal disease. Here, we describe 2 cases of hemangioma misdiagnosed as renal cell carcinoma before renal transplantation. The key finding in our case was the misdiagnosis of hemangiomas as renal cell carcinoma based on computed tomography and magnetic resonance imaging in patients with end-stage renal disease. Because living transplantation was planned for our patients, we performed rapid surgical resection of the heterogeneously enhancing renal masses to avoid delays in transplantation. Our case highlights the importance of rapid surgical resection of enhanced renal masses to confirm diagnosis, thereby avoiding delays in patients scheduled for renal transplantation.

Background: This study aimed to evaluate the efficacy and convenience of a chlorhexidine-coated hydrophilic urethral catheter compared with a conventional silicone Foley catheter, focusing on patient discomfort, procedural time, and clinician satisfaction. Methods: This prospective randomized controlled study enrolled patients who required short-term urethral catheterization at two hospitals. The patients were randomly assigned to receive either a conventional urethral catheter (control group, n=64) or a chlorhexidine-coated hydrophilic urethral catheter (intervention group, n=67). The primary endpoints were patient-reported pain scores during catheter insertion and removal (pain scale, 0–10), procedural time (seconds), and clinician-reported satisfaction (0–10). Results: Patients in the intervention group reported significantly less pain during catheter insertion (mean score, 4.2 vs. 6.6; p<0.01) and removal (mean score, 2.8 vs. 4.5; p<0.01). The mean procedural time was shorter in the intervention group (215 seconds vs. 386 seconds; p<0.01), and clinician satisfaction was higher (mean score, 8.2 vs. 3.6; p<0.01). Patients in the intervention group were more likely to experience mild pain during catheter insertion (score, 0–3; 26.9% vs. 12.7%; odds ratio [OR], 2.53) and removal (score, 0–3; 83.6% vs. 42.9%; OR, 6.79). A greater proportion of procedures was completed within 150 seconds (59.7% vs. 44.4%; OR, 1.85), and clinicians reported higher satisfaction with the procedure (score, 8–10; 73.1% vs. 23.4%; OR, 8.71). Conclusion Chlorhexidine-coated hydrophilic urethral catheters significantly reduced pain, shortened the procedural time, and improved clinician satisfaction. These findings suggest potential clinical benefits for both patients and clinicians.

Human papillomavirus (HPV) infections are linked to benign and malignant urogenital conditions, with varying risks associated with different HPV genotypes.Genital warts, mainly caused by low-risk HPV types, have seen a recent surge in incidence, leading to escalating medical costs. While vaccines like Cervarix and Gardasil target females, the exclusion of Gardasil 9 raises questions about gender-neutral vaccination strategies. Studies highlight potential cost savings through male HPV vaccination but note the rising prices of HPV vaccines, particularly Gardasil 9. Recent findings underscore HPV's expansion into nasopharyngeal cancer, urging the introduction of male HPV vaccination programs.However, the increasing vaccine costs raise concerns about accessibility and affordability. Regulatory bodies and healthcare stakeholders must address these challenges to ensure equitable HPV prevention and control measures. Efforts to control vaccine pricing and promote comprehensive immunization strategies are crucial in mitigating the growing burden of HPV-related diseases.

Materials and Methods: The medical records of 474 patients diagnosed with acute prostatitis between June 2006 and July 2022 were retrospectively reviewed. Patients in whom pathogens were not detected in serum or urine cultures were excluded. A total of 271 patients were included in the analysis. Patient characteristics and laboratory test results were compared between patients with acute prostatitis with and without liver abscesses. Results: Fifteen patients (5.5%) were identified with simultaneous liver abscesses and acute prostatitis. The liver abscess group was younger than the non-liver abscess group in terms of mean age. In the univariate analysis, a high proportion of patients had diabetes mellitus, whereas a low proportion had hypertension. None of the underlying diseases, including benign prostatic hyperplasia, malignancy, or alcoholism, demonstrated a significant association with liver abscess in multivariate analysis; however, an association was observed in liver function test results. All patients with liver abscesses tested positive for Klebsiella pneumoniae. Conclusions When K. pneumoniae is identified in patients with acute prostatitis and abnormal liver function tests, considering the possibility of metastatic infection in other organs, including the liver, and performing an active evaluation is essential.

Human papillomavirus (HPV) infections are linked to benign and malignant urogenital conditions, with varying risks associated with different HPV genotypes.Genital warts, mainly caused by low-risk HPV types, have seen a recent surge in incidence, leading to escalating medical costs. While vaccines like Cervarix and Gardasil target females, the exclusion of Gardasil 9 raises questions about gender-neutral vaccination strategies. Studies highlight potential cost savings through male HPV vaccination but note the rising prices of HPV vaccines, particularly Gardasil 9. Recent findings underscore HPV's expansion into nasopharyngeal cancer, urging the introduction of male HPV vaccination programs.However, the increasing vaccine costs raise concerns about accessibility and affordability. Regulatory bodies and healthcare stakeholders must address these challenges to ensure equitable HPV prevention and control measures. Efforts to control vaccine pricing and promote comprehensive immunization strategies are crucial in mitigating the growing burden of HPV-related diseases.

Human papillomavirus (HPV) infections are linked to benign and malignant urogenital conditions, with varying risks associated with different HPV genotypes.Genital warts, mainly caused by low-risk HPV types, have seen a recent surge in incidence, leading to escalating medical costs. While vaccines like Cervarix and Gardasil target females, the exclusion of Gardasil 9 raises questions about gender-neutral vaccination strategies. Studies highlight potential cost savings through male HPV vaccination but note the rising prices of HPV vaccines, particularly Gardasil 9. Recent findings underscore HPV's expansion into nasopharyngeal cancer, urging the introduction of male HPV vaccination programs.However, the increasing vaccine costs raise concerns about accessibility and affordability. Regulatory bodies and healthcare stakeholders must address these challenges to ensure equitable HPV prevention and control measures. Efforts to control vaccine pricing and promote comprehensive immunization strategies are crucial in mitigating the growing burden of HPV-related diseases.